HYBRID EVENT: You can participate in person at Madrid, Spain or Virtually from your home or work.

5th Edition of Cardiology World Conference

September 5-7, 2024 | Madrid, Spain

September 05 -07, 2024 | Madrid, Spain
CWC 2019

Mekhman N Mamedov

Mekhman N Mamedov, Speaker at Cardiovascular Conference
National Research Center for Preventive Medicine, Russian Federation
Title : Features of clinical and biochemical parameters, quality of life and prognosis of patients with CAD in combination with type 2 diabetes and COPD

Abstract:

Aim: Assessment of the clinical condition, quality and prognosis of life in a cohort of CAD patients in comorbidity with other chronic-non-communicable diseases (COPD and type 2 diabetes).

Materials and methods: A cohort study included 220 patients of both sexes aged 39 to 69 years old. In order to study the association of CAD with other NCD, the patients were divided into 3 groups: patients with CAD without comorbidity (group I, n = 80), with CAD and type 2 diabetes (group II, n = 70) and CAD with COPD (group III, n = 70). All patients underwent: history taking, ECG registration at rest, echoCG, and biochemical blood tests. Quality of life was assessed using the international questionnaire EQ-5D and the analog scale EQVas. To determine the prognosis of 10-year survival, the Charlson comorbidity index was used.

Results: The average SBP was the highest among patients with CHD and type 2 diabetes. According to EchoCG in the groups of patients with CAD with comorbidity, the average values of the interventricular septum thickness and left ventricular myocardial mass index were statistically significantly higher compared with the group of patients without comorbidity (117.03 ± 19.59 g (group II) vs 108.73 ± 27.44 g ( Group III) vs 99.15 ± 13.48 g (group I) - p <0.01). The level of triglycerides was highest in the group of CHD and type 2 diabetes, while other lipid metabolism indicators were comparable in all three groups. Evaluation of psychometric and physical parameters of quality of life showed that the severity of discomfort and decrease in mobility were significantly higher in groups with COPD and type 2 diabetes. According to the EQVas visual analogue scale, in the groups of patients with CAD and comorbidity, self-assessment of health was lower (p <0.01). An analysis of the 10-year survival prognosis for the Charlson comorbidity index showed that in both groups with comorbidity, this indicator was high compared with the control group, but in patients with CAD in combination with type 2 diabetes, its severity was 20% higher than in the group with COPD.

Conclusion: Thus, comorbidity of CAD with type 2 diabetes and COPD is associated with deterioration in the quality of life and a predicted survival rate for the comorbidity index. Patients with CAD and type 2 diabetes showed the worst indicators of prognosis, quality of life and clinical and biochemical parameters

Biography:

Professor Mehman Mamedov graduated from the Moscow Medical Academy named after I.M. Sechenov in 1993. He continued his medical residency at the Central Clinical Hospital of the Presidential Administration of the Russian Federation. In 1997 Dr. Mamedov received his PhD degree in the National Research Center for Preventive Medicine of the Ministry of Healthcare of the Russian Federation for research titled "Metabolic syndrome components in patients with arterial hypertension". In 2001 he wrote his doctoral thesis on "Clinical and biochemical features of metabolic syndrome and its pharmacological management". He has been working in the National Medical Research Center for Therapy and Preventive Medicine for 26 years, beginning as a researcher and eventually becoming the head of the scientific laboratory.

He is the author of 400 scientific works, 16 monographies in Russian, 4 monographies in English and 3 patents. Hirsch Index: RSCI — 36, Scopus — 6, Web of Science — 6. Under Dr. Mamedov’s supervision, 10 PhD and 1 doctoral thesis have been defended. Recently, Professor Mamedov M.N. has initiated 12 research projects, including some presented at the congresses of the American College of Cardiology, the European Society of Cardiology, the World Heart Federation, as well as at other international and national scientific events.

Professor Mamedov M.N. annually gives lectures in Russia and other countries. His research interests include: cardiometabolic disorders, lipid metabolism disorders, male health issues, cardiovascular risk assessment and correction, early markers of atherosclerosis, prediabetes and diabetes mellitus, risk factors and cardiovascular disease epidemiology, cardio-oncology, and comorbidities in internal medicine.

Dr. Mamedov is the editor-in-chef of the "International heart and vascular disease journal", member of the editorial board of the "Cardiology" and "Cardiovascular Prevention and Therapy" journals, head of the Department of Secondary Prevention of Chronic Noncommunicable Diseases of the National Medical Research Center for Therapy and Preventive Medicine, and President of the Cardioprogress Foundation.

Professor Mamedov M. was an executive secretary of the Russian National Congress of Cardiology for 6 years, organizing regional and national scientific conferences. He is one of the founders of the International Forum of Cardiology and Internal Medicine, which has been held annually at the Russian Academy of Sciences since 2012. He has letters of appreciation from the head of the Republic of Ingushetia, ministers of health of the Russian Federation, Uzbekistan, Tajikistan, Belarus, the Chechen Republic and the presidents of the Turkish Society of Cardiology, the Association of Internists of Kazakhstan and the National Health League. In 2019, he was awarded with V.D. Shervinsky medal by the President of the Russian Scientific Medical Society of Internal Medicine for his contribution to the development of medical science.

Watsapp